Clinical Trial: 19122

Trial Status: Open
Disease Type: Breast
Trial ID 19122
Sponsor ID EPIK-B3

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phoshpatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation

Principal Investigator
Alina M. Huang, MD
5 Locations

Locations

Arlington Office

Alexandria Office

Fairfax Office

Gainesville Office

Loudoun Office

Learn More About This Trial

Other Relevant Trials
Trial ID 22018
Sponsor ID Genentech

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Principal Investigator
Anne Favret, MD
3 Locations
Trial ID 21380
Sponsor ID post-MONARCH

postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Principal Investigator
Anne Favret, MD
3 Locations